Search Medical Condition
Please enter condition
Please choose location

Non-Small Cell Lung Cancer Clinical Trials

A listing of Non-Small Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (524) clinical trials

The relatively restricted C4.4a expression pattern provides a target for the selective delivery of a cytotoxic drug to C4.4.a-expressing tumor cells by means of a suitable antibody-drug conjugate. The subject population eligible for the current study will be those subjects with advanced malignancies known to express C4.4a, which are refractory ...

Phase

Determine the safety, tolerability and maximum tolerated dose of anetumab ravtansine (BAY 94-9343) in combination with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 in subjects with mesothelin-expressing predominantly epithelial mesothelioma or nonsquamous non-small-cell lung cancer.

Phase

- This is the first study where BAY1163877 is given to humans. Impact of the study is to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor. Patients (all comers) will receive the study drug treatment in a dose-escalation scheme ...

Phase

To characterize the safety, tolerability, pharmacokinetics and immunogenicity of anetumab ravtansine in subjects with advanced solid cancers and with different degrees of hepatic or renal impairment

Phase

Characterize the safety, tolerability, ECG effects, pharmacokinetics and immunogenicity of anetumab ravtansine given as single agent and after inhibition of CYP3A4 and P-gp by concomitant administration of itraconazole in subjects with mesothelin-expressing advanced solid cancers

Phase

The ATR(ataxia-telangiectasia and Rad3 related protein) inhibitor BAY1895344 is developed for the treatment of patients with advanced solid tumors and lymphomas. The purpose of the proposed trial is to evaluate the safety and tolerability of BAY1895344, and to identify the maximum tolerated dose of BAY1895344 that could be safely given ...

Phase

Study to evaluate the long-term safety and efficacy of Darbepoetin Alfa in anemic subjects with Advanced Stage Non-small Cell Lung Cancer receiving multi-cycle chemotherapy. Patient Inclusion Criteria: Subjects with metastatic (stage IV) Non-small Cell Lung cancer, receiving or about receive first line cyclic chemotherapy, life expectancy >6 months, 18 years ...

Phase

Patients with non-small cell lung cancer who have failed two or more prior treatment regimens, to determine overall survival Patient Inclusion Criteria: 18+ years of age, confirmed stage IIIB or non-small cell lung cancer, failed at least 2 prior systemic anti-cancer regimens, disease progression, Patient Exclusion Criteria: Presence of brain ...

Phase

First-line treatment for patients with non-squamous non-small cell lung cancer Patient Inclusion Criteria: Confirmed diagnosis, at least one measurable target lesion, 18+ years of age, life expectancy of >12 weeks Patient Exclusion Criteria: Small cell or carcinoid lung cancer patients are ineligible, untreated brain metastases, history of active malignancy in ...

Phase

First-line induction and maintenance therapy for the treatment of patients with Stage IV NSCLC Patient Inclusion Criteria: Must have a histologic or cytologic diagnosis of advance NSCLC, may not have received any prior systemic chemotherapy, 18 + years of age Patient Exclusion Criteria: Have a known central nervous system disease, ...

Phase